Sangamo Therapeutics Inc SGMO
$0.18 $0.04 (31.56%) 1D
Last Updated: May 04, 12:00 AM·OOTC
Pricing for US stocks is delayed by 24 hours
SGMO Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Sangamo Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Sangamo Therapeutics Inc. Stock Analysis SGMO
United States Health Care Micro Cap Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.
Sangamo Therapeutics Inc (SGMO) Chart
Financial Metrics & Statements of Sangamo Therapeutics Inc (SGMO)
FAQ's for Sangamo Therapeutics Inc (SGMO)
- As of August 2026, Sangamo Therapeutics Inc SGMO is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Sangamo Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Sangamo Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Sangamo Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Sangamo Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Sangamo Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Sangamo Therapeutics Inc (SGMO)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
